Dear Colleagues!

Could someone supply this article? We are willing to pay for it.

Thank you in advance.

Best Regards,


Judith Mills, MLIS, MS

Knowledge Manager Librarian

First DataBank, Inc.

701 Gateway Blvd Ste. 600

South San Francisco, CA 94080

Tel: (650)-246-2877


Clin Cancer Res. 2011 Feb 2. [Epub ahead of print]
Targeting Anaplastic Lymphoma Kinase in Lung Cancer.
Shaw AT<>, Solomon B<>.

Thoracic Oncology Center, Massachusetts General Hospital.

Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key regulators of signaling pathways controlling cell growth and differentiation. Deregulation of tyrosine kinase-mediated signaling occurs frequently in cancer and is believed to drive the initiation and progression of disease. Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) occur in a variety of human malignancies including non-small cell lung cancer (NSCLC), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors. The aberrant activation of ALK signalling leads to "oncogene addiction" and marked sensitivity to ALK inhibitors such as crizotinib (PF-02341066). This review will focus on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC. Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers, and to address the molecular basis for the development of resistance.

PMID: 21288922 [PubMed - as supplied by publisher]

This e-mail message is intended only for the personal use of the
recipient(s) named above. If you are not an intended recipient, 
you may not review, copy or distribute this message. If you have 
received this communication in error, please notify First DataBank
Support ([log in to unmask]) immediately by e-mail 
and delete the original message.